+44 115 7870500
DevelRx Logo
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact
DevelRx Logo
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact

Communications at scientific meetings

Numerous invited lectures at national and international scientific symposia in the fields of CNS disorders, drug abuse and obesity.

In addition, more than 500 communications have been given as oral presentations and posters at scientific symposia.

The Psychedelic Therapeutics and Drug Development Conference (Arrowhead Publishers' conferences) 5th May 2021.
How Non-clinical Research Can Inform the Clinical Development and Prescribing of Psychedelic Drugs

Evidence from non-clinical research with the ‘legacy’ psychedelics can help address important questions about tolerability, safety and abuse for the next generation of novel, psychedelic drugs that are being developed by the pharmaceutical industry

Psychedelic Therapeutics and Drug Development Conference, 4th-6th May 2021.
Talk entitled: “How non-clinical research can inform the clinical development and prescribing of psychedelic drugs.”

British Pharmacological Society (BPS), Laboratory Animal Science Association (LASA) & Psychiatry Consortium joint workshop, February 2021.
Talk entitled: “Exploring the Status of Preclinical Models of Psychiatric Disorders - Their Validity and Scope for Successful Translation.”

Dutch Paediatric Society (NVK; Nederlandse Vereniging voor Kindergeneeskunde) Virtual Meeting, December 2020. At the invitation of Takeda Pharmaceuticals, DevelRx continues its medical education support for psychiatrists and other healthcare providers treating attention deficit hyperactivity disorder.  
Talk entitled: “How can Pharmacology Help Determine Treatment Choice in ADHD?”

American College of Toxicology (ACT) Virtual Meeting, November 2020. Continuing Education Course.  
Talk entitled: “Understanding the Assessment of Abuse Potential: An Industry and Regulatory Perspective.”

Shire Psychiatry Educational Forum, 2019.
Talk entitled: “A place for amphetamines in clinical practice.”

College on Problems of Drug Dependence (CPDD) Workshop at the 80th Annual Meeting, 2018. Therapeutic Applications and Abuse Liability Assessment of Cannabidiol.  Talk entitled: “An evaluation of the discriminative and reinforcing properties of cannabidiol in rats."

Shire Symposium at the Eunethydis International Conference, 2018.  Making it HappenADHD Guidelines in Clinical Practice.
Talk entitled: “How can pharmacology help determine treatment choice in ADHD?”

Pinney Associates – RenaSci Supported International Webex2018. Developing Psychedelics into Medicine: Potential and Pitfalls.
Talk entitled: “Developing psychedelic drugs for medical use - dealing with the regulatory challenge of non-clinical abuse and dependence assessments.”

Cross Company Abuse Liability Council (C-CALC), 2018. Advancements and Challenges in Abuse Potential Evaluation.
Talk entitled: “An evidence-based evaluation of the possible influence of gender on results from drug-discrimination, intravenous self-administration and tolerance / dependence safety pharmacology testing.”

AddRess - Center for Addiction Research & Science, 2018.
Talk entitled: “Developing psychedelic drugs for medical use – regulatory challenges.”

DevelRx Logo


Pennyfoot Street,





Cookie PolicyPrivacy PolicyTerms & Conditions

Follow us on LinkedIn

Registered in England and Wales

Company number: 12028847